TerminatedNot Applicable

TDCS and Aphasia Therapy in the Acute Phase After Stroke

Stopped: Difficult patient recruitment

Belgium1 participantsStarted 2017-10-02

Plain-language summary

This study evaluates the neuromodulatory effect of combined tDCS and aphasia therapy in patients in the acute stage after stroke. Half of the participants will receive aphasia therapy and tDCS, the other half will receive aphasia therapy and sham-tDCS.

Who can participate

Age range18 Years – 85 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Diagnosed with mild-moderate aphasia (Token Test Score between 7 and 40) * Inclusion in the first few days after stroke (acute phase) * Age 18 - 85 years * Being right-handed * Mothertongue: Dutch * Able to undergo functional and specific linguistic testing and therapy in the acute phase following stroke * Imaging (CT or MRI) prior to inclusion (standard of care) * Signed Informed Consent Exclusion Criteria: * History of other diseases of the central nervous system, psychological disorders and (developmental) speech and or language disorders * Serious non-linguistic, cognitive disorders (as documented in the patients' medical history and inquired in anamneses) * Prior brain surgery * Excessive use of alcohol or drugs

What they're measuring

Change in naming performance

Timeframe: baseline, 1 week, 3 months, 6 months

Change in Vital Parameters

Timeframe: baseline, 1 hour (each session)

Trial details

NCT IDNCT03297450

SponsorUniversity Hospital, Ghent

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2018-03-30

View on ClinicalTrials.gov More Aphasia Following Cerebral Infarction trials